In the SONIC trial, TNF antagonist-naïve patients with moderate-to-severe CD who received Infliximab in combination with azathioprine had a significant benefit on the rates of corticosteroid-free clinical remission compared to those receiving Infliximab alone or azathioprine alone, with comparable toxicity among groups (Colombel et al., 2010). The gene discussed is TNF; the disease is Cowden disease.